share_log

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)

T2 Biosystems | SC 13G/A:超过5%持股股东披露文件(修正)-JACOB SAFIER(4.3%),NEW DIMENSIONS TRADING LTD.(4.3%)
美股SEC公告 ·  08/15 20:27

Moomoo AI 已提取核心信息

On April 12, 2024, T2 Biosystems, a medical device company, was the subject of a Schedule 13G filing with the SEC, indicating a change in ownership. The filing revealed that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a U.S. citizen, collectively reported beneficial ownership of 755,000 shares of T2 Biosystems' common stock, representing 4.3% of the company's class of securities. The shares reported in the filing are based on 17,479,954 shares outstanding as per T2 Biosystems' latest quarterly report filed on August 8, 2024. The filing, which was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of T2 Biosystems, nor is it connected with any transaction with such purpose or effect.
On April 12, 2024, T2 Biosystems, a medical device company, was the subject of a Schedule 13G filing with the SEC, indicating a change in ownership. The filing revealed that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a U.S. citizen, collectively reported beneficial ownership of 755,000 shares of T2 Biosystems' common stock, representing 4.3% of the company's class of securities. The shares reported in the filing are based on 17,479,954 shares outstanding as per T2 Biosystems' latest quarterly report filed on August 8, 2024. The filing, which was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of T2 Biosystems, nor is it connected with any transaction with such purpose or effect.
2024年4月12日,医疗器械公司t2 biosystems被证券交易委员会的13G陈述书披露,表明所有权发生了变化。该陈述书披露,总部位于开曼群岛的New Dimensions Trading Ltd.和美国公民Jacob Safier,共报告拥有755,000股t2 biosystems的普通股,占公司证券类别的4.3%。根据t2 biosystems于2024年8月8日提交的最新季度报告,陈述书中报告的股份基于17,479,954股流通股。该陈述书由New Dimensions Trading Ltd.的董事Chana Edelstein和Jacob Safier签署,声称所购买的股份不是为了改变或影响t2 biosystems的控制,也没有与此类目的或效果相关的任何交易。
2024年4月12日,医疗器械公司t2 biosystems被证券交易委员会的13G陈述书披露,表明所有权发生了变化。该陈述书披露,总部位于开曼群岛的New Dimensions Trading Ltd.和美国公民Jacob Safier,共报告拥有755,000股t2 biosystems的普通股,占公司证券类别的4.3%。根据t2 biosystems于2024年8月8日提交的最新季度报告,陈述书中报告的股份基于17,479,954股流通股。该陈述书由New Dimensions Trading Ltd.的董事Chana Edelstein和Jacob Safier签署,声称所购买的股份不是为了改变或影响t2 biosystems的控制,也没有与此类目的或效果相关的任何交易。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息